Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Clinical Trial to Evaluate VP-102 for the Treatment of Common Warts (Verruca Vulgaris)

Next Previous
X
Search
Trial Profile

A Phase 3 Clinical Trial to Evaluate VP-102 for the Treatment of Common Warts (Verruca Vulgaris)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cantharidin (Primary)
  • Indications Warts
  • Focus Registrational; Therapeutic Use
  • Sponsors Verrica Pharmaceuticals

    • Most Recent Events

    • 29 Feb 2024 According to a Verrica Pharmaceuticals media release, the Company will be seeking additional FDA feedback on its updated clinical design in the second quarter of 2024.
    • 29 Feb 2024 According to a Verrica Pharmaceuticals media release, company held a successful meeting with the FDA where we gained alignment on the Phase 3 clinical trial for evaluating YCANTH (VP-102) for the treatment of common warts.
    • 04 Jan 2024 According to a Verrica Pharmaceuticals media release, the company has received the minutes from the Company's recent Type C meeting with the U.S. Food and Drug Administration (FDA), which was held on November 6, 2023, to discuss the Phase 3 clinical development plan for YCANTH for the treatment of common warts.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top